JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rosenzweig-Lipson, S.
Right arrow Articles by Bergman, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rosenzweig-Lipson, S.
Right arrow Articles by Bergman, J.

Dopamine D1 receptor involvement in the discriminative-stimulus effects of SKF 81297 in squirrel monkeys

S Rosenzweig-Lipson and J Bergman

Harvard University, Department of Psychology, Cambridge, Massachusetts.

The discriminative-stimulus effects of the selective dopamine D1 agonist 6-chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-[1H]-3- benzazepine (SKF 81297) were investigated in squirrel monkeys trained to discriminate i.v. injections of SKF 81297 from saline in a two-lever drug-discrimination procedure. SKF 81297 produced dose-related increases in responding on the SKF 81297-associated lever with full substitution occurring at the training dose in all monkeys. Pretreatment with the selective D1 antagonist(-)-trans-6-7,7a,8,9,13b- hexahydro-3-chloro-2-hydroxy-N- methyl-5H- benzo(d)naphtho-(2,1- b)azepine 2-(SCH 39166) and the D1 partial agonist 7,8-dihydroxy-3- methyl-1-phenyl-2,3,4,5-tetrahydro-[1H]-3-benzazepine (SKF 75670) produced rightward shifts of the dose-effect curve for the discriminative-stimulus effects of SKF 81297, indicative of surmountable antagonism. Pretreatment with the selective D2 antagonist eticlopride, however, did not systematically alter the discriminative- stimulus effects of SKF 81297. Stereoselectivity was evident in the discriminative-stimulus effects of the enantiomers of the structurally related D1 agonist 3-allyl-6-bromo-7,8-dihydroxy-1-phenyl-2,3,4,5- tetrahydro-[1H]-3-benz azepin e (6-Br-APB), with the R-, but not the S- enantiomer, producing dose-related increases in responding on the SKF 81297-associated lever and full substitution in all monkeys. Another selective D1 agonist 6-chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro- 3-allyl-[1H]-3- benzazepine (SKF 82958) and the nonselective D1/D2 agonists (-)apomorphine and (-)4,6,6a,7,8,12b-hexahydro-7 methyl- indolo[4,3-ab]phenanthridine (CY 208-243), also engendered dose-related increases in SKF 81297-appropriate responding with full substitution occurring in one-half of the monkeys studied. The D2 agonists, (+)-4- propyl-9-hydroxynaphthoxazine and quinpirole, engendered dose-related increases in SKF 81297-appropriate responding but did not substitute fully in any monkey studied. Other dopaminergic drugs, including the D1 partial agonists SKF 75670 and R(+)-7,8-dihydroxy-1-phenyl-2,3,4,5- tetrahydro-[1H]-3- benzazepine (R-SKF 38393), and the indirect dopamine agonists, cocaine, d-amphetamine and 1-(2-[bis(4- fluorophenyl)methoxy]ethyl)-4-(3-phenylpropyl)piperazine (GBR 12909), did not substitute fully for SKF 81297 in any monkey studied. These results suggest that agonist actions at the D1 subtype of dopamine receptor are prominently involved in the discriminative-stimulus effects of SKF 81297.

Volume 267, Issue 2, pp. 765-775, 11/01/1993
Copyright © 1993 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
J. Neurosci.Home page
S. R. Vorel, C. R. Ashby Jr, M. Paul, X. Liu, R. Hayes, J. J. Hagan, D. N. Middlemiss, G. Stemp, and E. L. Gardner
Dopamine D3 Receptor Antagonism Inhibits Cocaine-Seeking and Cocaine-Enhanced Brain Reward in Rats
J. Neurosci., November 1, 2002; 22(21): 9595 - 9603.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
G. J. Carey and J. Bergman
Enadoline Discrimination in Squirrel Monkeys: Effects of Opioid Agonists and Antagonists
J. Pharmacol. Exp. Ther., April 1, 2001; 297(1): 215 - 223.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
M. R. Brandt, S. S. Negus, N. K. Mello, M. S. Furness, X. Zhang, and K. C. Rice
Discriminative Stimulus Effects of the Nonpeptidic delta -Opioid Agonist SNC80 in Rhesus Monkeys
J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1157 - 1164.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
J. W. Tidey and a. J. Bergman
Drug Discrimination in Methamphetamine-Trained Monkeys: Agonist and Antagonist Effects of Dopaminergic Drugs
J. Pharmacol. Exp. Ther., June 1, 1998; 285(3): 1163 - 1174.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
L. L. Demchyshyn, K. S. Sugamori, F. J. S. Lee, S. A. Hamadanizadeh, and H. B. Niznik
The Dopamine D1D Receptor
J. Biol. Chem., February 24, 1995; 270(8): 4005 - 4012.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1993 by the American Society for Pharmacology and Experimental Therapeutics.